Zaporožskij Medicinskij Žurnal (Oct 2016)

Clinical efficiency and dermoprotection of 2-ethyl-6-methyl-3-hydroxypyridine succinate drug in case of psoriasis: from the antioxidation point of view

  • V. A. Visir,
  • G. I. Makurina

DOI
https://doi.org/10.14739/2310-1210.2016.5.82598
Journal volume & issue
no. 5
pp. 31 – 38

Abstract

Read online

Objective. To study the clinical significance of oxidative processes modulation within frames of 2-ethyl-6-methyl-3-hydroxypyridine succinate dermatropic efficiency assessment in patients with psoriasis affected by arterial hypertension. Materials and methods. The results of this study are based on data of comprehensive examination and supervision of 30 patients suffering from psoriasis with different clinical forms such as normal levels of blood pressure (the control group) or in combination with hypertension (the study group). Results. The comparative description of the antioxidative therapy efficiency was performed by the end of treatment. The findings showed significantly positive antioxidant-dependent mechanisms of 2-ethyl-6-methyl-3-hydroxypyridine succinate clinical efficiency in patients with psoriasis affected by arterial hypertension. In case of patients with combined psoriasis and essential hypertension course 2-ethyl-6-methyl-3-hydroxypyridine succinate therapy caused reliable decrease of free-radical oxidation intensification in particular nitrosative (reliable decrease of nitrotyrosine) and oxidative (negative dynamics of endothelin-1 and positive dynamics as to glutathione metabolism) stresses. That, in its turn, decreased the evidence of apoptotic and inflammatory processes (caspase-8 and TNF-α regress) both directly and indirectly by means of mediating anti-inflammatory effect on endothelium cells and macrophages of anticoagulant proteinase through endothelial protein C receptor (EPCR) with production of components and structures of extracellular matrix and disturbance of microcirculation. Thus, it determines the key pathogenetic aspects of psoriasis. The decrease of VEGF expression indicators level (vascular endothelial growth factor) and serotonin, associated with this combined therapy, had stipulated statistically significant positive clinical and subjective effect in form of regress of dermatological changes (PASI index), decrease of itch (optimization of serotonin biosynthesis and reduction of methionine conversion (with homocysteine formation)) and improvement of life quality. Conclusions. Taking into account potential influence of 2-ethyl-6-methyl-3-hydroxypyridine succinate on these pathophysiological predictors and pathogenesis, which are to some extent involved in formation and progression of psoriatic disease, use of 2-ethyl-6-methyl-3-hydroxypyridine succinate is sufficiently effective in conditions of psoriasis therapy optimization.

Keywords